Treatment Guide
MFDS Classification of Stem Cell Therapies, Explained
How Korea's Ministry of Food and Drug Safety draws the line between drug and procedure — and why the distinction reads, on close inspection, rather more carefully than the consumer press allows.
The MFDS classification question is one of those distinctions the consumer press tends to flatten and the regulatory text rather insists upon — and the gap between the two registers is, on careful reading, where most of the substantive information sits. Korea's Ministry of Food and Drug Safety operates one of the more developed cellular-therapy frameworks in Asia, and the framework draws several distinctions the cosmopolitan reader is well served by understanding before any consultation. The principal axis is between cellular preparations classified as biological drugs — regulated under the Pharmaceutical Affairs Act and the Advanced Regenerative Bio Act — and cellular preparations performed as a procedure within a clinic's same-day workflow under the Medical Service Act. 藥同手術，分得好清楚, a Korean regulatory consultant once told me at a Hyatt lobby in Yongsan — meaning, simply, drug and procedure are kept distinct. The rest of the page follows from that observation.
The two regulatory pathways
Korea's MFDS regulates cellular therapies along two principal pathways, and the cosmopolitan reader who arrives at consultation expecting a single regulatory category will find, almost without exception, that the careful clinician begins by asking which pathway the treatment under discussion sits on. The first pathway is the biological-drug pathway: cellular preparations that have been substantially manipulated, expanded under good manufacturing practice, characterised through release testing, and approved for specific clinical indications. These are licensed products in the strict pharmaceutical sense, and the licensing dossier is reviewed on the same architecture used for any other biological drug — preclinical safety, clinical efficacy across phased trials, manufacturing controls, post-market surveillance. The product carries a registration number, a label, and a defined indication; the careful reader can verify the status against the MFDS public registry. A handful of allogeneic mesenchymal-stem-cell products and several autologous chondrocyte preparations sit on this pathway today.
The second pathway sits within the Medical Service Act and governs cellular procedures rather than cellular drugs — same-day, same-clinic preparations in which the patient's own tissue is harvested, minimally manipulated, and returned within a single clinical encounter. These are not regulated as products; they are regulated as the practice of medicine, and the framework reads more like a surgical-procedure framework than a pharmaceutical one. The clinic operates under the Medical Service Act licensing of the physician, the clinical environment, and the procedure itself; the cellular preparation is treated as a clinical step within a defined procedural workflow rather than as a standalone product. The two pathways co-exist by design; the careful clinic explains, on first inquiry, which pathway the treatment under discussion sits on, and the cosmopolitan reader is well served by asking the question plainly.
Substantial versus minimal manipulation
The substantial-versus-minimal manipulation distinction is the technical hinge on which the two pathways turn, and the cosmopolitan reader who reads the regulatory text directly will find the distinction set out in considerably more careful language than the consumer press uses. Minimal manipulation, in the MFDS construction broadly aligned with the U.S. FDA's 21 CFR 1271 framework, refers to processing steps that do not alter the relevant biological characteristics of the cells — washing, centrifugation, separation by density, mechanical disruption, and the isolation of a fraction without ex vivo expansion or genetic modification. The stromal vascular fraction prepared bedside from a small lipoaspirate is, in most readings, a minimally manipulated preparation; the cells are isolated from the surrounding tissue and the lipid fraction, but they are not expanded, not selected by surface marker, and not altered in their fundamental biology.
Substantial manipulation, by contrast, includes ex vivo expansion under cell-culture conditions, selection by specific surface markers, genetic modification, encapsulation, combination with non-biological scaffolds, or any processing step that alters the cells' biological function in a way the framework treats as creating a new product. A 2021 review in the Korean Journal of Internal Medicine surveyed the substantial-versus-minimal-manipulation literature and noted that the boundary remains an active area of regulatory science — though the field has, in broad terms, settled around the framework now in use. The practical effect, for the cosmopolitan reader, is that an autologous SVF preparation typically falls under the procedure pathway, while an allogeneic mesenchymal-stem-cell product expanded under GMP falls under the biological-drug pathway. The two preparations sit, in regulatory terms, on either side of a line drawn carefully and revisited as the science evolves.
A note on the same-day, same-clinic principle
The same-day, same-clinic principle is one of the structural features of the procedure pathway, and the careful reader should know that it is not a shorthand. The cells must, in regulatory terms, remain within the same clinical encounter and the same licensed facility from harvest to return. A preparation that leaves the clinic for processing at an off-site laboratory, or that is held overnight, generally crosses into the substantial-manipulation register and the biological-drug pathway.
The Advanced Regenerative Bio Act and what it added
The Advanced Regenerative Bio Act, which entered force in 2020 and was meaningfully amended through 2023 and 2024, sits alongside the Pharmaceutical Affairs Act and adds a third regulatory layer the cosmopolitan reader is well served by understanding. The Act establishes designated facilities — Advanced Regenerative Treatment Hospitals and dedicated cell-therapy centres — that can offer regenerative protocols under a framework intermediate between the biological-drug pathway and the standard procedure pathway. The framework permits, under specific institutional designations, certain protocols that would otherwise sit in the trial-only register, with patient registry enrolment, post-treatment surveillance, and outcome reporting as conditions of practice. Patients report, in published surveys, that the framework has materially expanded the accessible protocol set within Korea while keeping the surveillance and registry obligations rather more rigorous than in some neighbouring jurisdictions.
The Act also clarified the cell-therapy product approval pathway and introduced expedited review categories for products targeting rare disease indications, life-threatening conditions, and indications with substantial unmet clinical need. Several allogeneic mesenchymal-stem-cell products have moved through the expedited pathway in recent years; the careful reader can verify the current status against the MFDS public registry. The cosmopolitan traveller arriving in Seoul on a measured wellness itinerary will likely encounter clinics operating under one or the other or, in some cases, both frameworks — and the careful clinic should be able to explain, on first inquiry, which framework governs the specific protocol on offer. The conversation is, in the cosmopolitan register, not unlike asking a hotelier under which licence the spa floor operates; the answer is given without hesitation in a well-run establishment.
What the framework means for international patients
The framework's practical meaning, for the international patient arriving from Hong Kong, Singapore, Tokyo, or Sydney, sits in the documentation rather than in the brochure. A treatment performed under the procedure pathway should be supported, in the discharge file, by the clinic's Medical Service Act licensing, the operator's specialist credentials, and the procedure note that sets out the clinical workflow — harvest, processing, return — within the single encounter. A treatment performed under the biological-drug pathway should be supported by the product registration number, the lot certificate, the manufacturer's certificate of analysis, and the prescribing physician's documentation that the indication falls within the approved label or, where applicable, within an authorised off-label use. The cosmopolitan reader who leaves Seoul with both layers of documentation in hand will find the home-country claim, registry, or consultation correspondence rather lighter than otherwise.
A treatment performed under the Advanced Regenerative Bio Act framework — the third layer — should be supported by the institutional designation, the patient-registry enrolment, and the post-treatment surveillance schedule. Studies suggest that international patients who keep the surveillance correspondence with their home-country physician materially improve the continuity of care and any later insurance dialogue. The careful reader, in any of the three frameworks, asks the clinic's English-language patient coordinator at consultation what documentation will be provided and in what timeframe; the answer, in a well-run clinic, is given in writing rather than verbally. The U.S. National Institutes of Health maintains a public registry of cellular-therapy clinical trials at clinicaltrials.gov which can, in some cases, be useful at the documentation stage for indications that overlap registry-listed protocols.
How the three frameworks compare
The categorical comparison below sets out the three principal MFDS frameworks for the cellular-therapy reader. The reader is invited to read the table the way one reads an institutional directory — for the structural distinctions, not for any ranking.
| Dimension | Biological-drug pathway | Procedure pathway | Advanced Regenerative Bio Act |
|---|---|---|---|
| Governing statute | Pharmaceutical Affairs Act | Medical Service Act | Advanced Regenerative Bio Act |
| Manipulation | Substantial (GMP-expanded) | Minimal, same-day | Variable, designated facility |
| Approval unit | Product registration | Physician and facility | Institutional designation |
| Documentation | Lot certificate, label | Procedure note, MSA license | Registry, surveillance schedule |
| Indication breadth | Approved label only | Within physician practice | Registry-listed protocols |
| International-patient access | Standard medical-tourism | Standard medical-tourism | Eligibility-led |
| Surveillance obligation | Post-market PV | Routine adverse-event reporting | Active patient registry |
How to verify a clinic's regulatory position
Verification, in the cosmopolitan register, is less a question of sceptical investigation than of routine due diligence — the same discipline a careful traveller applies to a hotel review or a private-bank account opening, only with marginally different documents. The first verification, on inquiry, is the clinic's Medical Service Act licence, which is a public document and which the patient coordinator should be able to share without hesitation. The second is the operator's specialist licence and any subspecialty credentials relevant to the cellular indication on offer; these are also public, registered through the relevant Korean specialist board. The third — and this matters — is the regulatory framework under which the specific protocol is being offered, set out in plain language by the clinic before any deposit moves.
Where the protocol involves a biological-drug product, the careful reader asks for the product registration number and verifies it against the MFDS public registry. Where the protocol sits under the Advanced Regenerative Bio Act, the reader asks for the institutional designation and the registry-enrolment procedure. Where the protocol sits within the procedure pathway, the reader asks for the procedure note template and the documentation the clinic will provide post-treatment. The cosmopolitan reader who treats this as a brief, unhurried part of the consultation rather than as an interrogation will find the answers given in the same register the clinic uses for all other documentation — quietly, in writing, and as a matter of routine. Anything else is, in the careful reader's experience, a signal worth taking seriously.
How Korea's framework reads against neighbouring jurisdictions
The cosmopolitan reader who travels for treatment is well served by holding Korea's MFDS framework alongside the principal neighbouring frameworks — Japan's PMDA, Singapore's HSA, Hong Kong's Department of Health, and the U.S. FDA — rather than reading it in isolation. The frameworks share a great deal of structural language; they diverge, on careful inspection, in two or three places that materially affect what is available to the patient at consultation. Japan's PMDA operates a similarly tiered architecture, with the Act on the Safety of Regenerative Medicine providing a parallel to Korea's procedure pathway and the Pharmaceuticals and Medical Devices Act covering substantially manipulated cellular drugs. The framework is rigorous, the documentation register is comparable, and the Japanese clinics operating under the framework do so within a comparable surveillance discipline. The practical difference, for the cosmopolitan traveller, sits more in the protocol set on offer than in the regulatory architecture itself.
Singapore's HSA framework, established in 2021 and refined through 2023, sits closer to the European Medicines Agency's advanced-therapy medicinal-product architecture and is rather more conservative on the procedure-pathway side; same-day, same-clinic minimal-manipulation protocols are accessible but the registered-product set remains modest by comparison. Hong Kong, as discussed elsewhere in the gangnam-stem-cell register, regulates under the Pharmacy and Poisons Ordinance with a 2023 advanced-therapy review framework still bedding in. The U.S. FDA's 21 CFR 1271 framework is the reference architecture against which most Asian frameworks have been calibrated, and the substantial-versus-minimal-manipulation distinction reads in similar language across the four jurisdictions. The cosmopolitan reader who is choosing between Seoul, Tokyo, and Singapore for a regenerative consultation should weigh the protocol availability and the documentation standards alongside the regulatory architecture rather than as a substitute for it.
Where the framework is still evolving
The MFDS framework continues to evolve, and the cosmopolitan reader should know that the picture set out above is a fair reading of the position as of mid-2026 rather than a permanent settlement. Several areas of active regulatory work are worth flagging — not because they bear on any specific consultation today, but because the careful patient who returns to Seoul in twelve or twenty-four months may find one or two of the boundaries redrawn. The first is the boundary between minimal and substantial manipulation, which has been an area of comparative regulatory study across MFDS, the U.S. FDA, the EMA, and the PMDA, and which may be tightened in specific procedural contexts as the science settles. The second is the role of point-of-care devices that perform processing within the clinical encounter; these sit, today, mostly within the procedure pathway but are an area of attention.
The third is the Advanced Regenerative Bio Act's institutional designation framework, which has expanded since 2020 and which may be further refined to bring the patient-registry obligations and the surveillance schedule closer to international post-marketing surveillance norms. Patients report, in the published surveys, that the registry framework has been one of the more positively received features of the Act. Studies suggest the framework will continue to develop, and the careful reader who is thinking on a multi-year horizon will check the position before any subsequent treatment cycle. The framework, on careful reading, is doing what regulatory frameworks at their best do — drawing distinctions that the consumer press tends to flatten and revisiting them as the underlying science deepens.
Frequently asked questions
Is stem-cell therapy in Korea regulated as a drug or as a procedure?
Both — and which one applies depends on the specific protocol. Substantially manipulated cellular preparations expanded under GMP are regulated as biological drugs under the Pharmaceutical Affairs Act. Same-day, same-clinic preparations using minimally manipulated autologous cells are regulated as procedures under the Medical Service Act. A third framework, the Advanced Regenerative Bio Act, governs designated facilities offering specific registry-listed protocols.
What does substantial manipulation mean in the MFDS framework?
Substantial manipulation includes ex vivo expansion in culture, selection by surface marker, genetic modification, encapsulation, or combination with non-biological scaffolds. Minimal manipulation, by contrast, covers washing, centrifugation, density separation, and isolation without expansion. The boundary is broadly aligned with the U.S. FDA's 21 CFR 1271 framework and remains an area of active regulatory science.
Can international patients access protocols under the Advanced Regenerative Bio Act?
In principle, yes — though access is eligibility-led and tied to specific institutional designations and registry-enrolment requirements. The careful patient asks the clinic's English-language coordinator at consultation what designation governs the protocol on offer and what registry obligations apply, including any post-treatment surveillance schedule extending after departure from Korea.
How do I verify a clinic's regulatory position?
Three documents settle the question: the clinic's Medical Service Act licence, the operator's specialist credentials, and the regulatory framework governing the specific protocol on offer. Where a biological-drug product is involved, the product registration number can be verified against the MFDS public registry. The careful reader treats this as routine due diligence rather than interrogation.
What documentation should I leave Seoul with?
It depends on the framework. Procedure-pathway treatments should be supported by the procedure note and the MSA licensing. Drug-pathway treatments should be supported by the lot certificate, label, and prescribing documentation. Advanced Regenerative Bio Act treatments add the institutional designation and the registry-enrolment paperwork. A well-run clinic provides all relevant documentation in writing as a matter of routine.
Does the Advanced Regenerative Bio Act expand what is available?
It expands the accessible protocol set within designated institutional settings, while keeping surveillance and registry obligations rather more rigorous than in some neighbouring jurisdictions. The Act, which entered force in 2020 and has been meaningfully amended through 2023 and 2024, sits between the strict drug pathway and the standard procedure pathway.
Is the framework likely to change soon?
It continues to evolve. The minimal-versus-substantial-manipulation boundary, the role of point-of-care processing devices, and the institutional-designation framework under the Advanced Regenerative Bio Act are all areas of ongoing regulatory work. Studies suggest the framework will continue to develop, and the careful reader thinking on a multi-year horizon checks the position before each treatment cycle.